Associated Banc Corp Has $7 Million Holdings in Zoetis Inc. $ZTS

Associated Banc Corp cut its holdings in Zoetis Inc. (NYSE:ZTS) by 2.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,896 shares of the company’s stock after selling 923 shares during the period. Associated Banc Corp’s holdings in Zoetis were worth $7,002,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. Nova Wealth Management Inc. acquired a new position in shares of Zoetis during the 1st quarter valued at about $25,000. 1248 Management LLC acquired a new stake in Zoetis in the 1st quarter worth approximately $27,000. Saudi Central Bank bought a new stake in Zoetis during the first quarter worth approximately $29,000. REAP Financial Group LLC grew its holdings in Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares during the last quarter. Finally, NewSquare Capital LLC raised its position in shares of Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

Shares of ZTS stock opened at $122.80 on Tuesday. The stock has a market cap of $54.12 billion, a PE ratio of 21.14, a PEG ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $181.85. The firm’s 50 day moving average price is $137.28 and its two-hundred day moving average price is $149.86. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue for the quarter was up .5% on a year-over-year basis. During the same period last year, the company posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

Analyst Ratings Changes

A number of research firms recently issued reports on ZTS. Morgan Stanley lowered their target price on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research note on Monday, November 10th. JPMorgan Chase & Co. decreased their price target on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Stifel Nicolaus cut their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Finally, BTIG Research dropped their price objective on shares of Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a report on Wednesday, November 12th. Six research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $178.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.